Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2107-0180
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Phase 1 Study to Assess the Safety and Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Subjects Without Cystic Fibrosis With Moderate Hepatic Impairment ; volume:47 ; number:6 ; day:29 ; month:8 ; year:2022 ; pages:817-825 ; date:11.2022
European journal of drug metabolism and pharmacokinetics ; 47, Heft 6 (29.8.2022), 817-825, 11.2022

Urheber
Viswanathan, Lakshmi
Bachman, Eric
Tian, Simon
Ahluwalia, Neil
Zhang, Yaohua
Bernstein, Harold S.
Panorchan, Paul
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s13318-022-00791-8
URN
urn:nbn:de:101:1-2023011821381523626456
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:39 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Viswanathan, Lakshmi
  • Bachman, Eric
  • Tian, Simon
  • Ahluwalia, Neil
  • Zhang, Yaohua
  • Bernstein, Harold S.
  • Panorchan, Paul
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations

Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis

Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience

Verbundene Objekte